BRISTOL-MYERS SQUIBB COMPANY (BMY) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 768.00M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 42.09B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | Commercial Paper |
| Cash and current securities | 11.07B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities · Commercial Paper |
| Total assets | 87.63B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $768.00M | $42.09B | (m) | $11.07B | $87.63B | (m) |
| 2026-03-31 | (m) | (m) | $1.99B | $42.15B | (m) | $10.49B | $86.48B | (m) |
| 2025-12-31 | (m) | (m) | $1.98B | $42.85B | (m) | $10.67B | $90.04B | (m) |
| 2025-09-30 | (m) | (m) | $4.25B | $44.47B | (m) | $16.50B | $96.89B | (m) |
| 2025-06-30 | (m) | (m) | $4.47B | $44.47B | (m) | $13.60B | $94.68B | (m) |
| 2025-03-31 | (m) | (m) | $3.35B | $46.16B | (m) | $11.78B | $92.43B | (m) |
| 2024-12-31 | (m) | (m) | $1.83B | $47.60B | (m) | $10.86B | $92.60B | (m) |
| 2024-09-30 | (m) | (m) | $873.00M | $48.67B | (m) | $8.09B | $93.67B | (m) |
| 2024-06-30 | $52.22B | $45.56B | $3.09B | $48.86B | $266.00M | $6.65B | $94.65B | 55.17% |
| 2024-03-31 | $55.35B | $45.68B | $2.87B | $49.49B | $2.99B | $9.67B | $99.03B | 55.89% |
| 2023-12-31 | (m) | (m) | $2.87B | $36.65B | (m) | $12.28B | $95.16B | (m) |
| 2023-09-30 | (m) | (m) | $4.87B | $32.14B | (m) | $7.68B | $91.26B | (m) |
| 2023-06-30 | (m) | (m) | $2.41B | $34.66B | (m) | $8.73B | $93.49B | (m) |
| 2023-03-31 | (m) | (m) | $2.25B | $35.08B | (m) | $9.27B | $94.28B | (m) |
| 2022-12-31 | (m) | (m) | $3.90B | $35.06B | (m) | $9.25B | $96.82B | (m) |
| 2022-09-30 | (m) | (m) | $1.90B | $36.97B | (m) | $9.03B | $98.20B | (m) |
| 2022-06-30 | (m) | (m) | $4.65B | $37.11B | (m) | $13.23B | $100.36B | (m) |
| 2022-03-31 | (m) | (m) | $7.30B | $37.45B | (m) | $14.97B | $103.03B | (m) |
| 2021-12-31 | (m) | (m) | $4.76B | $39.60B | (m) | $16.97B | $109.31B | (m) |
| 2021-09-30 | (m) | (m) | $4.77B | $39.68B | (m) | $15.66B | $110.89B | (m) |
| 2021-06-30 | (m) | (m) | $2.50B | $42.50B | (m) | $12.97B | $110.80B | (m) |
| 2021-03-31 | (m) | (m) | $1.50B | $44.51B | (m) | $12.93B | $112.44B | (m) |
| 2020-12-31 | (m) | (m) | $2.00B | $48.34B | (m) | $15.83B | $118.48B | (m) |
| 2020-09-30 | (m) | (m) | $3.25B | $41.36B | (m) | $21.16B | $125.54B | (m) |
| 2020-06-30 | (m) | (m) | $4.25B | $41.85B | (m) | $21.66B | $128.08B | (m) |
| 2020-03-31 | (m) | (m) | $3.26B | $42.84B | (m) | $18.32B | $129.28B | (m) |
| 2019-12-31 | (m) | (m) | $2.76B | $43.39B | (m) | $15.39B | $129.94B | (m) |
| 2019-09-30 | (m) | (m) | $0.00 | $24.39B | (m) | $32.54B | $57.43B | (m) |
| 2019-06-30 | (m) | (m) | $0.00 | $24.43B | (m) | $29.36B | $55.16B | (m) |
| 2019-03-31 | (m) | (m) | $0.00 | $5.63B | (m) | $8.76B | $34.83B | (m) |
| 2018-12-31 | $6.89B | $1.99B | $1.25B | $5.65B | $0.00 | $8.88B | $34.99B | 19.71% |
| 2018-09-30 | $6.93B | $104.00M | $1.25B | $5.69B | $0.00 | $6.83B | $33.73B | 20.55% |
| 2018-06-30 | $6.93B | $857.00M | $1.26B | $5.67B | $0.00 | $6.08B | $32.64B | 21.24% |
| 2018-03-31 | $7.02B | $250.00M | $1.25B | $5.78B | $0.00 | $6.77B | $33.08B | 21.22% |
| 2017-12-31 | (m) | (m) | (m) | $6.97B | $299.00M | $6.81B | $33.55B | (m) |
| 2017-09-30 | (m) | (m) | (m) | $6.98B | $799.00M | $7.12B | $33.98B | (m) |
| 2017-06-30 | (m) | (m) | $750.00M | $6.91B | (m) | $6.50B | $33.41B | (m) |
| 2017-03-31 | (m) | (m) | $749.00M | $7.24B | (m) | $6.11B | $32.94B | (m) |
| 2016-12-31 | (m) | (m) | $749.00M | $5.72B | (m) | $6.35B | $33.71B | (m) |
| 2016-09-30 | (m) | (m) | $749.00M | $5.84B | (m) | $5.56B | $33.73B | (m) |
| 2016-06-30 | (m) | (m) | (m) | $6.58B | (m) | $4.65B | $32.83B | (m) |
| 2016-03-31 | (m) | (m) | (m) | $6.59B | (m) | $4.31B | $31.89B | (m) |
| 2015-12-31 | (m) | (m) | (m) | $6.55B | (m) | $4.27B | $31.75B | (m) |
| 2015-09-30 | (m) | (m) | (m) | $6.63B | (m) | $5.41B | $31.78B | (m) |
| 2015-06-30 | (m) | (m) | (m) | $6.62B | (m) | $5.48B | $31.95B | (m) |
| 2015-03-31 | (m) | (m) | (m) | $7.13B | (m) | $7.61B | $33.58B | (m) |
| 2014-12-31 | (m) | (m) | (m) | $7.24B | (m) | $7.43B | $33.75B | (m) |
| 2014-09-30 | (m) | (m) | (m) | $7.27B | (m) | $7.22B | $33.45B | (m) |
| 2014-06-30 | (m) | (m) | (m) | $7.37B | (m) | $7.17B | $33.50B | (m) |
| 2014-03-31 | (m) | (m) | (m) | $7.37B | (m) | $7.06B | $33.42B | (m) |
| 2013-12-31 | (m) | (m) | (m) | $7.98B | (m) | $4.53B | $38.59B | (m) |
| 2013-09-30 | (m) | (m) | $30.00M | $6.53B | (m) | $2.72B | $36.80B | (m) |
| 2013-06-30 | (m) | (m) | $680.00M | $6.44B | (m) | $2.80B | $36.25B | (m) |
| 2013-03-31 | (m) | (m) | $658.00M | $6.52B | (m) | $2.53B | $35.96B | (m) |
| 2012-12-31 | (m) | (m) | (m) | $6.57B | (m) | $2.83B | $35.90B | (m) |
| 2012-09-30 | (m) | (m) | $619.00M | $6.61B | (m) | $2.93B | $36.04B | (m) |
| 2012-06-30 | (m) | (m) | (m) | $5.21B | (m) | $5.04B | $31.67B | (m) |
| 2012-03-31 | (m) | (m) | (m) | $5.27B | (m) | $5.03B | $32.41B | (m) |
| 2011-12-31 | (m) | (m) | (m) | $5.38B | (m) | $8.73B | $32.97B | (m) |
| 2011-09-30 | (m) | (m) | (m) | $5.44B | (m) | $8.19B | $32.01B | (m) |
| 2011-06-30 | (m) | (m) | (m) | $5.33B | (m) | $7.67B | $31.83B | (m) |
| 2011-03-31 | (m) | (m) | (m) | $5.28B | (m) | $6.79B | $30.85B | (m) |
| 2010-12-31 | (m) | (m) | (m) | $5.33B | (m) | $7.30B | $31.08B | (m) |
| 2010-09-30 | (m) | (m) | (m) | $6.48B | (m) | $8.36B | $31.89B | (m) |
| 2010-06-30 | (m) | (m) | (m) | $6.25B | (m) | $7.45B | $31.05B | (m) |
| 2010-03-31 | (m) | (m) | (m) | $6.08B | (m) | $6.78B | $30.75B | (m) |
| 2009-12-31 | (m) | (m) | (m) | $6.13B | (m) | $8.51B | $31.01B | (m) |
| 2009-09-30 | (m) | (m) | (m) | $6.31B | (m) | $6.67B | $30.95B | (m) |
| 2009-06-30 | (m) | (m) | (m) | $6.24B | (m) | $8.12B | $29.81B | (m) |
| 2008-12-31 | (m) | (m) | (m) | $6.58B | (m) | $8.27B | $29.49B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |